

Docket No.: 28646/42267
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Roger Melton et al.

Application No.: 10/590,789

Confirmation No.: 8378

Filed: February 12, 2007

Art Unit: 1651

For: Use of Carboxypeptidase G for Combating
Antifolate Toxicity

Examiner: S. M. Hanley

RESPONSE TO RESTRICTION REQUIREMENT

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the Office Action of December 23, 2009, applicants hereby elect the invention represented by the claims of examiner's Group I, namely, claims 1-19, 25-46, 62, and 63, without traverse, for examination on the merits at this time.

Applicants also elect the following species, without traverse:

Claim 2 antifolate compound – tomudex;

Claim 12 inhibited enzyme – GARFT;

Claim 13 antifolate compound – LY309887;

Claim 39 antifolate compound – AG2037; and

Claim 43 disease – cancer.

Claims readable upon the elected species are 1-19, 25-46, 62, and 63. An early and favorable action on the merits is respectfully requested.